CoChat
Sign Up
Cited by 57Endometrial and Cervical Cancer TreatmentsEstrogen and related hormone effectsBreast Cancer Treatment Studies

The DOI matches its Crossref record; 43 of the 47 references it cites were found in a registry or an index.

The Analyses of 17β-Hydroxysteroid Dehydrogenase Isozymes in Human Endometrial Hyperplasia and Carcinoma1

Utsunomiya, Hiroki, Suzuki, Takashi, Kaneko, Chika, Takeyama, Junji, Nakamura, Junji, Kimura, Kenichi, Yoshihama, Makoto, Harada, Nobuhiro, Ito, Kiyoshi, Konno, Ryo, Sato, Shinji, Okamura, Kunihiro, Sasano, Hironobu·2001·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jcem.86.7.7661
Open this paper in CoChat — free account

Abstract

Intratumoral metabolism and synthesis of estrogens are considered to play very important roles in the pathogenesis and development of human endometrial adenocarcinoma. The 17beta-hydroxysteroid dehydrogenase (17beta-HSD) isozymes catalyze the interconversion of estradiol (E2) and estrone and thereby serve to modulate the tissue levels of bioactive E2. To elucidate the possible involvement of this enzyme in human endometrial carcinoma, we first examined the expression of 17beta-HSD type 1 and type 2 in 20 normal cycling human endometria, 36 endometrial hyperplasia, and 46 endometrial endometrioid adenocarcinoma using immunohistochemistry, and we then studied immunoreactivity of 17beta-HSD type 2 using immunoblotting analyses, the activity of 17beta-HSD type 1 and type 2 using thin-layer chromatography and their expression using RT-PCR in endometrial endometrioid adenocarcinoma. We correlated these findings with various clinicopathological parameters to examine the biological significance of 17beta-HSDs in human endometrial disorders. 17beta-HSD type 2 immunoreactivity in normal endometrium was present in all cases of secretory phase (n = 14), but not in any endometrial mucosa of proliferative phase (n = 6). In addition, 17beta-HSD type 2 immunoreactivity was detected in 27 of 36 (75%) endometrial hyperplasia and 17 of 46 (37%) carcinoma cases. 17beta-HSD type 1 immunoreactivity was not detected in all the cases examined. In both endometrial hyperplasia and carcinoma cases there were significant positive correlations between 17beta-HSD type 2 and progesterone receptor labeling index (LI). In carcinoma cases, a significant inverse correlation was detected between 17beta-HSD type 2 immunoreactivity and age. In addition, 17beta-HSD type 2 immunoreactivity was also correlated with 17beta-HSD type 2 enzymatic activity, and semiquantitative analyses of 17beta-HSD type 2 messenger RNA. No significant correlations were detected between 17beta-HSD type 2 and estrogen receptor LI, Ki67 LI, amount of aromatase messenger RNA or histological grade. These data indicated that the expression of 17beta-HSD type 2 in hyperplastic and/or neoplastic endometrium may represent altered cellular features through hyperplastic and neoplastic transformation. However, 17beta-HSD type 2 may also play some protective and/or suppressive roles toward unopposed estrogenic effects through inactivating E2 in situ, especially in premenopausal patients.

Overview

Integrity signals

Registry

Crossref · 10.1210/jcem.86.7.7661

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

4 of the 47 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

See all 57

Related

See all

Metadata

Authors
Utsunomiya, H., Suzuki, T., Kaneko, C., Takeyama, J., Nakamura, J., Kimura, K., Yoshihama, M., Harada, N., Ito, K., Konno, R., Sato, S., Okamura, K., & Sasano, H.
Affiliations
  • Tohoku University (JP)
  • Megmilk Snow Brand (Japan) (JP)
  • Fujita Health University (JP)
Corresponding author
Utsunomiya, Hiroki
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2001-07
Volume
86
Issue
7
Pages
3436-3443
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jcem.86.7.7661
OpenAlex
W2116219667
Cited by
57
References
47
Citations by year
2024: 1 · 2023: 1 · 2022: 1 · 2020: 2 · 2019: 1 · 2018: 5 · 2017: 3 · 2016: 2 · 2014: 2 · 2013: 2 · 2012: 3
FWCI
3.46
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (11470047)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
17β-hydroxysteroid dehydrogenase, endometrial hyperplasia, endometrial adenocarcinoma, endometrioid carcinoma, estrogen metabolism, estradiol, estrone, progesterone receptor, estrogen receptor, endometrial cycle
MeSH terms
Adenocarcinoma, Endometrial Hyperplasia, Female, Humans, Immunohistochemistry, Isoenzymes, Menstrual Cycle, Receptors, Progesterone, RNA, Messenger, 17-Hydroxysteroid Dehydrogenases, Immunoblotting, Gene Expression, Endometrial Neoplasms, Reverse Transcriptase Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review